Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma

NACompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Lymphoma, Non-HodgkinCentral Nervous System Neoplasms
Interventions
DIAGNOSTIC_TEST

18F-FDG

PET scan with 18F-FDG as a tracer, taken both for primary staging and therapy assessment.

DIAGNOSTIC_TEST

18F-fluciclovine

PET scan with 18F-fluciclovine as a tracer, taken both for primary staging and response to therapy assessment.

DIAGNOSTIC_TEST

standard MRI

clinical routine MRI examination, both for primary staging and response to therapy assessment.

Trial Locations (1)

Unknown

Norwegian University of Science and Technology, Department of Circulation and Medical Imaging, Trondheim

All Listed Sponsors
collaborator

St. Olavs Hospital

OTHER

lead

Norwegian University of Science and Technology

OTHER

NCT03188354 - Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma | Biotech Hunter | Biotech Hunter